PATIENT SAFETY INFORMATION CARD



Soliris can lower the ability of your immune system to fight infections, especially meningococcal infection, which requires immediate medical attention. If you experience any of the following symptoms, you should immediately call your doctor or seek emergency medical care, preferably in a major emergency medical care center:

- · headache with nausea or vomiting
- headache with a stiff neck or stiff back
- fever
- rash
- confusion
- · muscle aches with flu-like symptoms
- · eyes sensitive to light



Get emergency medical care right away if you have any of these signs or symptoms and show this card.

Even if you stop using Soliris, keep this card with you for 3 months after your last Soliris dose. Your risk of meningococcal infection may continue for several weeks after your last dose of Soliris.

PATIENT SAFETY INFORMATION CARD

Information for the Treating Physician



This patient has been prescribed Soliris® (eculizumab) therapy, which increases the patient's susceptibility to meningococcal infection (Neisseria meningitidis) or other general infections.

- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early
- Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary
- Contact prescribing physician (below) as soon as possible

For more information about Soliris, please refer to the full Summary of Product Characteristics, as approved by the Israeli MOH, or e-mail: drugsafety@neopharmgroup.com .In case of safety concerns, call 1-800-250-255.

Patients receiving Soliris should carry this card at all times.
Show this card to any doctor involved in your health care.

Patient name	
Hospital where treated	
Physician name	
Tel. number	
Vaccination date	







This document was last approved in Mar/2021 By The Israeli Ministry of Health (MOH)